Hervé Affagard is the CEO and co-founder of MaaT Pharma and president of Alliance Promotion Microbiote. We sat down with him to discuss the company's promising lead product for gastrointestinal acute graft-versus-host disease.
A rising demand for biologics means that biotech companies face a multitude of manufacturing challenges, but also plenty of opportunities. We spoke to Kevin Sharp, senior VP and head of sales at Samsung Biologics, to examine what is driving this demand...
Novo Nordisk's Ozempic (semaglutide) took the weight loss sector by storm in 2023, propelled by strong efficacy and safety data, coupled with social media buzz and celebrity endorsements that elevated the drug to mainstream prominence.
Eligo Bioscience, a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures.
MaaT Pharma, a clinical-stage biotech company developing microbiome ecosystem therapies, has presented positive results from a recent study investigating its lead product MaaT013 for patients with steroid-refractory (SR) or steroid-dependent (SD) gastrointestinal...
Candel Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead adenovirus asset CAN-2409, for the treatment of pancreatic cancer.
UK-based Lindus Health and US-based Thirty Madison today (December 14) announced they have completed the enrolment of a trial to assess their personalized dermatology telemedicine platform, Facet.
Biotech company SolasCure has announced the results of its proof-of-concept phase 2 trial investigating its wound gel for chronic venous leg ulcer patients.
Biosenic, a company specializing in serious autoimmune and inflammatory diseases and cell therapy, has secured funding from Singapore-based TrialCap, in a bid to accelerate its phase 3 clinical development.
ViroCell Biologics, a London-based viral vector CDMO for cell and gene therapy clinical trials, has partnered with University College London (UCL) to advance its pediatric cancer treatment.
Skye Bioscience has announced its plans to develop nimacimab, the company’s monoclonal antibody recently acquired from Bird Rock Bio, for weight loss and the treatment of obesity.
Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation to support its vaccine development efforts.
Dr. Michael O’Neal, chief medical officer at Clario, believes that many drugs ultimately fail due to common operational and data challenges that could, and should, be corrected.
CASI Pharmaceuticals and Juventas Cell Therapy recently received approval from China's National Medical Products Administration (NMPA) for Yuanruida, a domestic CD19-targeting CAR-T therapy for relapsed/refractory B-Cell Acute Lymphocytic Leukemia.
Symbiosis Pharmaceutical Services can now test small molecule, biological and advanced therapeutical medicinal products (ATMP) following a £1 million investment.
Eli Lilly has invested in its manufacturing capacity once more and has announced plans to build a $2.5 billion high-tech manufacturing site in Germany.
We sat down with Cary Claiborne, CEO and president of Adial Pharma, to discuss the challenges of treating alcohol abuse and company's solution – a serotonin-3 receptor antagonist that could affect neurotransmitters like dopamine and modulate the...
London-based sustainable technologies company Johnson Matthey has partnered with biotechnology firm Basecamp Research to adopt more sustainable, bio-based catalysts.
GSK CEO Emma Walmsley has told Reuters that the company’s respiratory syncytial virus (RSV) vaccine is expected to make over $1.26 billion in its first year on the market.
AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.
A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.
Lumen Bioscience, a clinical-stage biopharma company developing biologic drugs for highly prevalent disease, has received $5.5 million in new funding from the U.S. Department of Defense, to develop technologies for needle-free vaccines.
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), has received approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
Sofia Baig is the president of clinical solutions at Precision for Medicine. As a strategic industry leader, she is adept driving organizational change and delivering top- and bottom-line growth.
Outsourcing Pharma is delighted to invite you to join our not-to-be-missed webinar on one of the most important areas of the industry – patient centricity – and its solutions.
Sanofi is planning to expand the market for its best-selling anti-inflammatory drug Dupixent, used to treat COPD, also known as ‘smokers lung’, after a successful second phase 3 trial.
Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are common in solid tumors, including lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
At the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia, Arrowhead Pharmaceuticals unveiled the phase 2 clinical data for plozasiran (ARO-APOC3) and zodasiran (ARO-ANG3).
The FDA has delayed its decision on whether to approve Bristol Myers Squibb and 2seventy bio’s CAR-T cell therapy, as it plans to seek further advice from experts.
Oxford-based SynaptixBio, whose aim is to find a treatment for TUBB4A-related leukodystrophies, has been awarded a £490,000 BioMedical Catalyst grant from Innovate UK to tackle less common variants of the disease.
At last month’s CPHI Barcelona, Sirio launched its new ready-to-market menopause and eye health softgels in a bid to collaborate with over the counter (OTC) brands and large pharmacy chains looking to advance to market faster.
Verici Dx, a company developing advanced clinical diagnostics for organ transplant, has entered into a global licensing partnership with healthcare giant Thermo Fisher to develop an assay for pre-transplant kidney testing.
Valneva recently received the greenlight for IXCHIQ by the US Food and Drug Administration (FDA), marking the approval of the world’s first chikungunya vaccine.
Cynthia Pussinen knew she wanted to work in STEM fields by the time she was a teenager, she received a full scholarship to study nuclear engineering but after two years changed to chemistry for her major.
Glox Therapeutics, a company developing precision antibiotic therapies based on naturally occurring bacteriocins, has raised £4.3m in seed funding to develop targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
Ever since injections promising to help people lose weight hit the shelves, interest around the world has been phenomenal. So high was demand, companies were finding it difficult to keep up with the demand.
IO Biotech, a clinical-stage biopharma company developing therapeutic cancer vaccines, has completed enrollment in its phase 3 trial for IO102-IO103, in combination with KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with advanced melanoma....
Angle, a liquid biopsy company with circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, has launched its Portrait PD-L1 test for the evaluation of PD-L1 protein expression on CTCs.